Zegalogue

(Dasiglucagon)

Zegalogue

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous; 0.6 mg/0.6 mL)
Drug ClassAntihypoglycemic agents
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

Product Monograph / Prescribing Information

Document TitleYearSource
Zegalogue (dasiglucagon) Prescribing Information. 2023Rechon Life Science AB Malmö, Sweden

Systematic Reviews / Meta-Analyses